A preference for gepants: Limitations of current first- and second-line acute treatments for migraine

Treatments for migraine have previously been limited to non specific medicines, such as non-steroidal anti-inflammatory drugs (NSAIDs), analgesics or the use of migraine-specific triptans.¹ While some of these treatments are currently the recommended first- and second-line choices for migraine,² they have some prominent limitations, highlighting the need for alternative tr